Optimization of atopic dermatitis treatment that requires second-line systemic therapy through multiomic predictive models of treatment response (DermAtOmics-II) - DermAtOmics-II

Hospital Universitario La Paz0 个研究点目标入组 150 人开始时间: 2023年6月13日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Cohort 1: Subjects diagnosed with moderate-severe atopic dermatitis who are going to receive second-line systemic treatment; Cohort 2: Subjects diagnosed with moderate-severe atopic dermatitis who are already receiving second-line systemic therapy at the time of selection., Participants must be willing and able to provide written informed consent prior the initiation of any study procedures., For children, parent/legal guardian must provide written informed consent. If age >11 years old, the minor must give assent., Participant is willing and able to adhere to the procedures specified in this protocol.

•Any investigational drug within 60 days prior to study drug administration., Any condition or situation precluding or interfering the compliance with the protocol., Women of childbearing potential must have a negative urine pregnancy test at Screening and Day 0., Women of childbearing potential must commit not to become pregnant. They must be willing to use highly effective contraceptive methods or have practiced sexual abstinence during the study.

发起方